10x Genomics Inc. (TXG)

Processing plant tie-ins and restart complete; commercial production expected in coming weeks(All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - March 2...

I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption, particu...

Drilling success continues to support reserve life extensions (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - March 19, 2025) - Torex Gold Resources...

Compelling results return multiple high-grade intercepts at both Media Luna East and West (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - February 2...

2024 marks another solid year of operational and financial results; on track to return to positive free cash flow generation by mid-2025 (All amounts expressed in U.S. dollars unless otherwise stated)...

On Wednesday, 10x Genomics Inc TXG reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of $(0.30).

10x Genomics, Inc. (NASDAQ:TXG ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Cassie Corneau - Senior Director, IR and Strategic Finance Serge Saxonov - CEO and C...

The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street e...

10x Genomics (TXG) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.41 per share a year ago.

Besides Wall Street's top -and-bottom-line estimates for 10x Genomics (TXG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during th...